Rheumatology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Cystatin C is a sensitive marker for detecting a reduced glomerular filtration rate when assessing chronic kidney disease in patients with rheumatoid arthritis and secondary amyloidosis
Scandinavian Journal of Rheumatology , 10/02/09

Sato H et al. – Serum cysC can identify a reduced GFR more accurately than sCr-eGFRs. Serum cysC > 1.09 mg/L could be a marker of a reduced GFR, and serum cysC > 1.365 mg/L would strongly suggest a reduced GFR in patients who have RA with secondary amyloidosis.

Methods

50 patients with RA and secondary amyloidosis (mean age 60.9 ± 11.2 years; 45 women) were evaluated
Revised 24-h creatinine clearance (r24-hCCr), was determined by multiplying original value by 0.719, used as reference for GFR
Screening potential of serum cysC and some estimates of GFR calculated from serum cysC (cysC-eGFR: eGFRHoek and eGFRRule) for detecting reduced GFR analysed

Results

Both cysC-eGFRs strongly correlated with r24-hCCr
Difference between the eGFRRule and average r24-hCCr was small
eGFRHoek and sCr-eGFR were higher than eGFRRule and r24-hCCr
In receiver operating characteristic (ROC) curve analyses of reduced GFR, serum cysC gave a greater area under curve than the sCr-eGFR
Specificity and PPV 100% when serum cysC > 1.365 mg/L was used

<< Previous
Positive anti-citrullinated protein antibody status and small...

Next >>
The impact of systemic lupus erythematosus on employment